Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: Results from a Delphi panel

Clinical and Translational Oncology

Volumn 13, Issue 7, 2011, Pages 460-471

  Isla, Dolores ^a   González Rojas, Nuria ^b   Nieves, Diana ^c   Brosa, Max ^c   Finnern, Henrik W ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b Boehringer Ingelheim SA   (Spain)

^c Oblikue Consulting   (Spain)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Costs; Delphi panel; NSCLC; Spain; Use of resources

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CLINDAMYCIN; DEXAMETHASONE; DOCETAXEL; DOXYCYCLINE; ERLOTINIB; ERYTHROMYCIN; FENTANYL; GEMCITABINE; HYDROXYZINE; IBUPROFEN; LACTULOSE; LOPERAMIDE; MEGESTROL ACETATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MORPHINE; NAVELBINE; ONDANSETRON; OXYCODONE; PACLITAXEL; PEMETREXED; PREDNICARBATE; PREDNISONE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER FATIGUE; CANCER PALLIATIVE THERAPY; CLINICAL DECISION MAKING; CONSTIPATION; COST BENEFIT ANALYSIS; DELPHI STUDY; DIARRHEA; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFECTION; LENGTH OF STAY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; RASH; SPAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; ECONOMICS; HEALTH CARE PLANNING; LUNG TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; LUNG NEOPLASMS; SPAIN;

EID: 82255169622     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0683-0     Document Type: Article

References (43)

1. Instituto Salud Carlos III. National Center of Epidemiology (2010) Available at: http://www.isciii.es/htdocs/centros/epidemiologia/epi-cancer.jsp. Accessed: May 2010
2. Fernández de Larrea-Baz N, Alvarez-Martín E, Morant-Ginestar C et al (2009) Burden of disease due to cancer in Spain. BMC Public Health 9:42
3. Schrump DS, Giaccone G, Kelsey C et al (2008) Non-small cell lung cancer. In: DeVita V, Lawrence T, Rosenberg S. Cancer. Principles & practice of oncology. Lippincott Williams & Wilkins, Philadelphia, USA, p 896-946
4. Sant M, Allemani C, Santaquilani M et al (2009) Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45:931-991
5. Abal J, Ramos MA, de la Infanta RG et al (2006) [Lung cancer diagnosis: hospitalization costs]. Arch Bronconeumol 42:569-574 (Pubitemid 44912989)
6. Hirsh V (2010) Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17:13-23
7. Spiro SG, Tanner NT, Silvestri GA et al (2010) Lung cancer: progress in diagnosis, staging and therapy. Respirology 15:44-50
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
9. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388
10. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
11. Gridelli C, Aapro M, Ardizzoni A et al (2005) Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23:3125-3137 (Pubitemid 46224136)
12. Stinchcombe TE, Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6:233-241
13. Kadam UT, Jordan K, Croft PR (2006) A comparison of two consensus methods for classifying morbidities in a single professional group showed the same outcomes. J Clin Epidemiol 59:1169-1173 (Pubitemid 44485427)
14. Felip E, Garrido P, Trigo JM et al (2009) SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 11:284-289
15. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 26:3543-3551
16. Azzoli CG, Baker S Jr, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266
17. E-Salud. Spanish Health Costs Database (2010) Oblikue Consulting. Available at: http://www.oblikue.com/bddcostes/. Accessed: May 2010
18. General Spanish Council of Pharmacist. Database of Medicines (2010). Available at: http://www.portalfarma.com. Accessed: May 2010
19. Kosmidis PA, Kalofonos HP, Christodoulou C et al (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115-122
20. Heymach JV, Paz-Ares L, De Braud F et al (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415
21. Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-smallcell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024 (Pubitemid 46606280)
22. Chang JW, Tsao TC, Yang CT et al (2008) A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer. Chang Gung Med J 31:559-566
23. Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478-1484 (Pubitemid 32488857)
24. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 22:2184-2191 (Pubitemid 41095154)
25. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597 (Pubitemid 41079796)
26. Quoix E, Breton JL, Ducoloné A et al (2005) First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer 47:405-412 (Pubitemid 40248745)
27. Jassem J, Ramlau R, Karnicka-Mlodkowska H et al (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12:1375-1381 (Pubitemid 33100241)
28. Belani CP, Ramalingam S, Perry MC et al (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced nonsmall-cell lung cancer. J Clin Oncol 26:468-473 (Pubitemid 351171701)
29. Socinski MA, Weissman C, Hart LL et al (2006) Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24:4840-4847 (Pubitemid 46630910)
30. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al (2006) Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12:6049-6055 (Pubitemid 44703768)
31. Jackman DM, Yeap BY, Lindeman NI et al (2007) Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760-766 (Pubitemid 350002874)
32. Lynch TJ, Fenton D, Hirsh V et al (2009) A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 4:1002-1009
33. Georgoulias V, Androulakis N, Kotsakis A et al (2008) Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 59:57-63
34. Gridelli C, Kaukel E, Gregorc V et al (2007) Single-agent pemetrexed or sequential pemetrexed/ gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2:221-229 (Pubitemid 47181327)
35. Chen YM, Perng RP, Shih JF et al (2008) A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable nonsmall cell lung cancer in the elderly. Lung Cancer 61:214-219
36. Navaratnam S, Kliewer EV, Butler J et al (2010) Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 70:110-115
37. Lyseng-Williamson KA (2010) Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 28:75-92
38. Rubio-Terrés C, Tisaire JL, Kobina S et al (2002) Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced nonsmall-cell lung cancer. Lung Cancer 35:81-89 (Pubitemid 34028095)
39. Sacristán JA, Kennedy-Martin T, Rosell R et al (2000) Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/ cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer 28:97-107 (Pubitemid 30136409)
40. Schiller J, Tilden D, Aristides M et al (2004) Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43:101-112 (Pubitemid 38096299)
41. Ferriols Lisart F, Pitarch Molina J, Magraner Gil J (2006) [Pharmacoeconomic assessment of taxanes as first-line therapy for advanced or metastatic nonmicrocytic lung cancer]. Farm Hosp 30:211-222 (Pubitemid 44580101)
42. Carlson JJ, Veenstra DL, Ramsey SD (2008) Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 68:1105-1113 (Pubitemid 351693678)
43. Molinier L, Combescure C, Chouaïd C et al (2006) Cost of lung cancer: a methodological review. Pharmacoeconomics 24:651-659 (Pubitemid 43998818)